Your Article Summary
See Latest ArticlesNovel treatment strategies for malignant gliomas using neural stem cells
Neurotherapeutics, 07/01/09
Oh MC et al. - In a review of novel treatment strategies for malignant gliomas using neural stem cells (NSCs), it was concluded that these studies and others on the basic biology of both brain tumor stem cells (BTSCs) and NSCs will be crucial to expanding treatment strategies for malignant gliomas.
Methods- Identification and characterization of endogenous NSCs, especially those in the adult human brain, have inspired new ideas for selectively targeting and destroying malignant gliomas.
- Gliomas consist of a heterogeneous population of cells, and some of these cells have characteristics of cancer stem cells.
- These BTSCs share certain characteristics with normal NSCs.
- It is still unclear whether malignant gliomas in human pts originate from these aberrant BTSCs.
- Cellular and molecular similarities between BTSCs and normal NSCs suggest a common research landscape underlying both normal and cancer stem cell biology, wherein findings of 1 field are relevant to the other.
- The natural tropism of NSCs to gliomas has generated the idea that modified NSCs can deliver modified genes to selectively destroy malignant brain tumor cells, and even BTSCs, while leaving healthy surrounding neurons intact.
Related Articles
MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells
Journal of Neuro-Oncology, 11/04/09
Relevance Score: 68%
Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma
The Journal of Nuclear Medicine, 11/18/09
Relevance Score: 67%
A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma
Anticancer Research, 11/13/09
Relevance Score: 67%
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Neuro-Oncology, 10/06/09
Relevance Score: 67%
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Neuro-Oncology, 10/06/09
Relevance Score: 67%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A heritable predisposition to pituitary tumors
Pituitary, 12/18/09
Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor
Pituitary, 12/18/09
Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/18/09